{"text": "TITLE:\n      Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy\nSUMMARY:\n      The objective of this study is to demonstrate the efficacy and safety of Privigen in\n      subjects with CIDP.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n        IVIG-untreated subjects:\n          -  Either subjects with newly diagnosed CIDP (developing over at least 2 months) or\n             subjects with an IVIG treatment interruption for at least 1 year with a progressive\n             disease (deteriorating in the last 2 months) prior to enrolment.\n          -  Actual diagnosis (including electrophysiology) of CIDP with progressive or relapsing\n             dysfunction from motor and sensory or symmetric motor nerve only in at least 1 limb\n             resulting from neuropathy. Criteria for definite or probable CIDP according to\n             EFNS/PNS guideline.\n          -  Age \u226518 years.\n          -  Male or female.\n          -  Written informed consent for study participation obtained before undergoing any study\n             specific procedures.\n        IVIG-pretreated subjects:\n          -  Being treated regularly with IVIG on a fixed cycle length of 2 to 6 weeks \u00b1 5 days in\n             the last 6 months, on a fixed dosage of \u00b1 20 % in the last 6 months and deteriorating\n             by at least 1 INCAT score point during the Washout Period of up to 10 weeks (except\n             for an increase from 0 to 1 solely due to upper limb score).\n          -  Historic diagnosis of CIDP with progressive or relapsing dysfunction from motor and\n             sensory or symmetric motor nerve only in at least 1 limb resulting from neuropathy.\n             Criteria for definite or probable CIDP according to EFNS/PNS guideline.\n          -  Age \u226518 years.\n          -  Male or female.\n          -  Written informed consent for study participation obtained before undergoing any study\n             specific procedures.\n        Exclusion Criteria:\n          -  A motor syndrome that fulfils criteria for multifocal motor neuropathy (MMN) with\n             conduction block (i.e., upper limb motor weakness without sensory deficit and with a\n             50% decrease in action potential amplitude or area on proximal compared with distal\n             stimulation in motor nerves).\n          -  CIDP with monoclonal gammopathy of uncertain significance (CIDP-MGUS) with anti-MGUS\n             antibodies and patients with distal acquired demyelinating symmetric\n             (DADS)neuropathy.\n          -  Any disease (mainly neurological or chronic orthopedic) that may cause symptoms or\n             may interfere with treatment or outcome assessments with the INCAT (e.g., diphtheria,\n             drug or toxin exposure and diabetes mellitus likely to have caused the neuropathy,\n             IgM paraproteinemia, familial neuropathy, borreliosis with radiculopathy,\n             post-polio-syndrome,M. Parkinson, stroke).\n          -  Current malignancy.\n          -  History of cardiac insufficiency (New York Heart Association [NYHA] III/IV),\n             cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or\n             advanced ischemic heart disease, congestive heart failure or severe hypertension.\n          -  History of thrombotic episodes (deep vein thrombosis, myocardial infarction,\n             cerebrovascular accident).\n          -  Migraine associated with IVIG infusion in the last 3 months prior to enrolment.\n          -  Known allergic or other severe reactions to blood products including intolerability\n             to previous IVIG (i.e. severe headache, hypersensitivity, intravascular hemolysis).\n          -  Subjects with serum IgA level less than 50% of the lower normal limit.\n          -  Known hyperprolinemia.\n          -  Any condition (including alcohol, drug or medication abuse) that is likely to\n             interfere with evaluation of the study product or satisfactory conduct of the study.\n          -  Plasma exchange 3 months prior to enrolment.\n          -  Treatment with immunomodulatory agents others than steroids, methotrexate or\n             azathioprine (e.g. interferon, TNF-\u03b1 inhibitors) within 6 months before enrolment.\n          -  Treatment with rituximab in the 12 months before enrolment.\n          -  Abnormal laboratory parameters: creatinine > 1.5 times the upper normal limit (UNL),\n             lactate dehydrogenase (LDH) > 1.5 times the UNL, C-reactive protein (CRP) > 1.5 times\n             the UNL, hemoglobin (Hb) < 10 g/dL.\n          -  Ongoing HIV, hepatitis C and hepatitis B infection.\n          -  Participation in another clinical study (or use of another investigational medicinal\n             product [IMP]) within 3 months prior to enrolment\n          -  Not able to comply with study procedures and treatment regimen.\n          -  Employee at the study site, or spouse/partner or relative of any study staff (e.g.,\n             investigator, sub-investigators, or study nurse).\n          -  Pregnancy or nursing mother.\n          -  Intention to become pregnant during the course of the study.\n          -  Female subjects of childbearing potential either not using, or not willing to use, a\n             medically reliable method of contraception for the entire duration of the study, or\n             not sexually abstinent for the entire duration of the study, or not surgically\n             sterile.\n", "cuis": "C0393819 C3542501 C2342400 C0947630 C1552616 C1706244 C0018017 C2239270 C2979883 C2342400 C0947630 C0393819 C0243161 C0013893 C0243161 C0332155 C0011900 C1408353 C3844638 C0393819 C1561542 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C1561543 C3839460 C2266640 C1457868 C0012634 C0018609 C1561542 C1446476 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C0393819 C3839460 C0501384 C0332516 C0015385 C0277785 C0442874 C0042075 C0243161 C0393819 C0963149 C0282423 C0162791 C0220845 C1114365 C0947630 C0009797 C0025664 C0184661 C1552740 C0056685 C0332155 C1457868 C1561542 C0025344 C1140618 C0153664 C1269078 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C0393819 C0277785 C3839460 C1552658 C1552723 C2004062 C0501384 C0442874 C0042075 C0332516 C0015385 C0282423 C0162791 C0220845 C0243161 C0393819 C0963149 C1114365 C0947630 C0009797 C0025664 C0184661 C1552740 C0243161 C0235025 C0028866 C1135343 C0039082 C0206064 C0796095 C0796110 C2936859 C2936904 C0243161 C3843228 C0748618 C1834697 C1140618 C0153664 C1269078 C3714552 C0028778 C1552007 C2222792 C0501384 C1292856 C1515885 C0026470 C1136085 C0272247 C0087130 C0393819 C3495458 C0813154 C0332516 C3245488 C1457887 C0012634 C0018609 C2707261 C3845870 C1261322 C0031809 C0220825 C0870300 C0012546 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C3806166 C0011849 C0011878 C0455488 C0743140 C0011860 C1313937 C0040537 C2229950 C0442874 C0042075 C0013227 C1254351 C0030489 C0700594 C0032586 C1610087 C0006035 C0442874 C0042075 C0202084 C0039082 C0206064 C0796095 C0796110 C2936859 C2936904 C0038454 C0032371 C0242422 C0006826 C1306459 C3842363 C0018801 C0018802 C0264714 C0004083 C0086168 C0262926 C2004062 C0018787 C0153500 C0153957 C1281570 C0003811 C0494598 C0878544 C1837350 C2721728 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0443343 C0018802 C0264719 C0264722 C0742758 C2039715 C0151744 C1313980 C0010054 C1510446 C0264694 C0020538 C1963138 C1696708 C2748577 C0947663 C1306232 C0027051 C2926063 C0155668 C0428953 C0264708 C0155626 C1273976 C0746727 C2348362 C1168331 C0455406 C0340324 C1998297 C0340312 C0340325 C0428950 C2825159 C0149871 C0857136 C0340708 C0042487 C0459853 C0262926 C2004062 C2674163 C0038454 C3536593 C0149931 C0724401 C0574032 C0854643 C1561542 C0456388 C1306232 C0000828 C0442740 C3845888 C0235574 C0865236 C2030603 C0020517 C0520946 C0441750 C0013182 C0016470 C0037296 C0079840 C0585186 C4062895 C0011432 C0085636 C0151206 C0301925 C0577628 C0949570 C1405033 C2957106 C2229758 C2229759 C2229760 C2229761 C2229762 C1553386 C0268528 C0260268 C0013146 C0012634 C3864998 C0009647 C0871117 C0001962 C0001975 C0013227 C1254351 C0220825 C1261322 C1444296 C1444299 C0947630 C1547307 C0032113 C1561542 C0025677 C0087111 C1533734 C3887704 C0746919 C0001551 C1527392 C0005525 C0004482 C0021747 C0733470 C3652465 C0021740 C0751598 C0002199 C0593974 C0172511 C0982327 C1522537 C1561542 C0087111 C1533734 C3887704 C0746919 C0393022 C1561542 C1553386 C0028378 C0013418 C0449381 C0201975 C1561535 C0201657 C0973334 C1455884 C0428528 C0376261 C1881354 C0027270 C0518015 C0948093 C2216252 C1561562 C2239101 C0019034 C0546660 C1168591 C1168592 C0037054 C0019163 C0276609 C4075603 C0011226 C0019159 C0019196 C0814152 C2063407 C0524909 C0085293 C0854496 C0019158 C3245491 C1552578 C0013230 C0220825 C1261322 C0947630 C1553756 C1553854 C3272565 C1561542 C0025664 C0184661 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0040808 C2945654 C0947630 C1299581 C1549590 C0557351 C1578434 C3245489 C0947630 C1551040 C3172260 C0947630 C0032961 C3484365 C0425965 C3843687 C3843688 C3843689 C3843690 C3843691 C3843692 C0028678 C0237094 C0237133 C0237142 C0237155 C0237161 C0237162 C0237169 C0237178 C0237185 C0237206 C0237221 C0237228 C0237247 C0237255 C0237276 C0237283 C0237289 C0237305 C0237318 C0237324 C0237338 C0237357 C0237361 C0237369 C0237373 C0237380 C0237387 C1948167 C1948168 C1948169 C1948170 C1948171 C1948173 C1948174 C1948176 C1948178 C1948179 C1948180 C1948181 C0162425 C0549206 C0947630 C0600109 C0558080 C2222792 C0700589 C0344221 C0493327 C0877698 C0086286 C0086580 C3858758 C0025663 C0025664 C0947630 C0332534 C0720099 C2926735 C0947630 C0543467 C0332534 C0720099 C2926735 C0021359 ", "concepts": "Chronic Inflammatory Demyelinating Polyneuropathy, Acute Inflammatory Demyelinating Polyneuropathy, Privigen, Study summary, summary Objective, objective, Objective, Privigen, study cidp criteria, Eligibility Criteria untreated diagnosed, Undiagnosed, Either, cidp, month Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, year, Nonprogressive, interruption IVC deteriorating, disease, h disease, month electrophysiology, diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis, cidp, Nonprogressive motor nerve, symmetric, limb, Dysfunction neuropathy, uropathy, Criteria, cidp, definity Guideline, Guideline, guidelines Age study, informed consent form procedures, Procedures, specific cyclen, untreated deteriorating, month Period Upper limb, Upper limb, Upper limb diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis, cidp, Dysfunction, Nonprogressive, Historical, Historical, Historical motor nerve, neuropathy, uropathy, symmetric, limb Guideline, Guideline, guidelines, Criteria, cidp, definity Age study, informed consent form procedures, Procedures, specific Criteria motor neuropathy, Oculomotor neuropathy, Acute motor neuropathy, syndrome, syndrome X, syndrome c, W syndrome, N syndrome, G syndrome, criteria, Multifocals sensory deficit, No sensory deficit, Upper limb, Upper limb, Upper limb, weakness, block action, OT potential motor nerves, stimulation, Acustimulation mgus, monoclonal gammopathies, Biclonal gammopathy, uncertain, cidp antibodies, Antibodies, symmetric, acquired symptoms, disease, h disease, Neurological, ICU.neurological assessment, Assessment, Assessment, Assessment, diphtheria, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, Poor outcome diabetes mellitus (DM), diabetes mellitus diet, H/O: diabetes mellitus, diabetes mellitus risk, NIDDM diabetes mellitus, FH: Diabetes mellitus, toxin exposure, dioxin exposure, neuropathy, uropathy, drug, drug paraproteinemia, radiculopathy, Polyradiculopathy, CMV radiculopathy, borreliosis, neuropathy, uropathy, IgM syndrome, syndrome X, syndrome c, W syndrome, N syndrome, G syndrome, stroke, polio, Parkinsonism malignancy, Malignancy, No malignancy Cardiac insufficiency, Cardiac insufficiency, Acute cardiac insufficiency, Association, Dissociation, History, History, Hearts, Heart, Heart, Heart cardiac dysrhythmia, Other cardiac dysrhythmias, cardiomyopathy, No cardiomyopathy, HIV cardiomyopathy, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, unstable CHF - Congestive heart failure, Acute congestive heart failure, Chronic congestive heart failure, congestive heart failure symptom, systolic congestive heart failure, IHD - Ischemic heart disease, FH: Ischemic heart disease, ischaemic heart disease, Acute ischemic heart disease, Chronic ischemic heart disease, hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, severed Myocardial infarction, NOS, Myocardial infarction, Healed myocardial infarction, ECG: myocardial infarction, atrial myocardial infarction, Acute myocardial infarction, First myocardial infarction, septal myocardial infarction, Septal myocardial infarction, Apical myocardial infarction, FH: Myocardial infarction, Silent myocardial infarction, Recent myocardial infarction, Lateral myocardial infarction, Aborted myocardial infarction, ECG: no myocardial infarction, Date of myocardial infarction, deep vein thrombosis (DVT), Left deep vein thrombosis, Deep vein thrombosis, leg, vein thrombosis, H/O: Deep vein thrombosis, History, History, Thrombotic episodes cerebrovascular accident, Chronic cerebrovascular accident Migraines, Wigraine, infusion, Reinfusion, month blood products, severed, Abreactions, No reactions, Known allergy intravascular hemolysis, Acute intravascular hemolysis, acute intravascular hemolysis, hypersensitivities, Hypersensitivity, hypersensitivity types, hypersensitivity; drug, food hypersensitivity, hypersensitivity tests, milk hypersensitivity, Skin hypersensitivity, Oral hypersensitivity, Tooth hypersensitivity, Light hypersensitivity, Scalp hypersensitivity, Other hypersensitivity, latex hypersensitivity, wheat hypersensitivity, pain; hypersensitivity, severe headache serum IgA, serum IgD, serum IgE, serum IgG, serum IgM, normal hyperprolinemia Medication abuse, Medication abuse, condition, Condition, conditioning, precondition, alcohol, alcohol, drug, drug Evaluation, Evaluation, OT evaluation, Pt evaluation, study, Satisfactory Plasma exchange, month methotrexate, treatment, Treatment, treatment, No Treatment, immunomodulators, Immunomodulators, Immunomodulators azathioprine, Interferon, Interferon, Interferon, Ginterferon, Ginterferon, interferon A, 2 interferon, interferon-aB, peginterferon, Interferons, month treatment, Treatment, treatment, No Treatment, rituximab, month normal, normal laboratory, Abnormal labor, Parameters, Creatinine, Creatinine C-reactive protein level, C-reactive protein hs, Elev C-reactive protein, C-reactive protein level, lactate, L-lactate, Codehydrogenase I Haemoglobin, hemoglobins s, hemoglobin D, Hemoglobin, Hemoglobin, hemoglobin sc, Methemoglobin, Oxyhemoglobin, oxyhemoglobin, hemoglobin; S hepatitis B, acute hepatitis B infection, Occult hepatitis B infection, hepatitis D, hepatitis, Hepatitis C, hepatitis g, hepatitis E infection, chronic hepatitis B infection, hepatitis e, hepatitis h, hepatitis investigational, investigation, investigational drug, Investigation, Investigation, study, ParticipationMode, ParticipationType, Clinical month procedures, Procedures, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, regimen, regimen, study, able Employee, Employed, spouse, spouse, study, staff, Relative study pregnancy, Pregnancy, ? Pregnancy, Pregnancy 6, Pregnancy 5, Pregnancy 4, Pregnancy 3, Pregnancy 2, Pregnancy 1, nursing, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other, other Intention, pregnant, study willing, Unwilling, OT potential contraception, IUD contraception, CAP contraception, CAP contraception, Contraception;F, Contraception;M, reliable, method, methods, study, Induration, Duration, Duration study, Surgically, Induration, Duration, Duration sterile "}
